← Back to Clinical Trials
Recruiting NCT06661278

NCT06661278 Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06661278
Status Recruiting
Phase
Sponsor Royal Brompton & Harefield NHS Foundation Trust
Condition Long QT Syndrome
Study Type OBSERVATIONAL
Enrollment 110 participants
Start Date 2025-03-18
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 16 Years
Study Type OBSERVATIONAL
Interventions
Exercise tolerance testPhysical activity & heart rate monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 110 participants in total. It began in 2025-03-18 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to evaluate exercise testing and daily physical activity in children and adolescents who are diagnosed with an inherited arrhythmia. The main question it aims to answer is: Does maximum heart rate during controlled exercise tolerance testing accurately reflect maximum heart rate and peak exercise levels during free living daily physical activity in children and adolescents diagnosed with an inherited arrhythmia? Participants will: * Complete routine exercise tolerance testing * Record daily physical activity and exercise over two weeks, while wearing an activity and heart rate monitor and digit diary. * Complete a physical activity questionnaire at the end of two weeks.

Eligibility Criteria

Inclusion Criteria: Affected cohort * Male and female children * Aged 6-16 years * Diagnosed with long QT syndrome or catecholaminergic polymorphic ventricular tachycardia * Treated with beta-blocker and/or sodium channel blockade * Able to complete a treadmill ETT Healthy cohort * Male and female children * Aged 6-16 years * Siblings of affected children (gene negative) * Undergoing IAS screening * Able to complete a treadmill ETT Exclusion Criteria: * Children aged less than 6 years * Adults, 17 years of age and above * Unable to run on an exercise treadmill due to physical limitations. * Individuals unable to speak or understand English, due to no translation service available. * Pregnancy

Contact & Investigator

Central Contact

Catherine E Renwick

✉ c.renwick@rbht.nhs.uk

📞 07968534941

Principal Investigator

Catherine E Renwick

PRINCIPAL INVESTIGATOR

Royal Brompton & Harefield NHS Foundation Trust

Frequently Asked Questions

Who can join the NCT06661278 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 16 Years, studying Long QT Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06661278 currently recruiting?

Yes, NCT06661278 is actively recruiting participants. Contact the research team at c.renwick@rbht.nhs.uk for enrollment information.

Where is the NCT06661278 trial being conducted?

This trial is being conducted at London, United Kingdom, Sutton, United Kingdom.

Who is sponsoring the NCT06661278 clinical trial?

NCT06661278 is sponsored by Royal Brompton & Harefield NHS Foundation Trust. The principal investigator is Catherine E Renwick at Royal Brompton & Harefield NHS Foundation Trust. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology